NASDAQ:OMER - Omeros Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.83
  • Forecasted Upside: 134.20 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$15.30
▲ +0.24 (1.59%)

This chart shows the closing price for OMER by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omeros Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMER and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMER

Analyst Price Target is $35.83
▲ +134.20% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Omeros in the last 3 months. The average price target is $35.83, with a high forecast of $100.00 and a low forecast of $12.00. The average price target represents a 134.20% upside from the last price of $15.30.

This chart shows the closing price for OMER for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Omeros. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/21/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2021WBB SecuritiesBoost Price TargetStrong-Buy$75.00 ➝ $100.00Medium
4/26/2021HC WainwrightLower Price TargetBuy$34.00 ➝ $32.00Medium
2/1/2021UBS GroupInitiated CoverageBuy$25.00Low
1/20/2021HC WainwrightBoost Price TargetBuy$31.00 ➝ $34.00High
1/4/2021HC WainwrightReiterated RatingBuy$32.00 ➝ $31.00N/A
12/4/2020Maxim GroupBoost Price TargetBuy$20.00 ➝ $25.00Low
11/23/2020HC WainwrightReiterated RatingBuy$32.00Medium
10/20/2020Bank of AmericaInitiated CoverageBuy$21.00High
9/1/2020WedbushLower Price TargetNeutral$17.00 ➝ $12.00High
8/21/2020HC WainwrightLower Price TargetBuy$34.00 ➝ $32.00High
8/14/2020Maxim GroupLower Price TargetBuy$25.00 ➝ $20.00Low
6/9/2020WedbushReiterated RatingHold$17.00Medium
5/12/2020Needham & Company LLCReiterated RatingHoldHigh
5/12/2020HC WainwrightReiterated RatingBuy$34.00High
4/27/2020WedbushReiterated RatingHold$17.00Low
3/4/2020WedbushReiterated RatingHold$18.00 ➝ $22.00Medium
3/3/2020HC WainwrightReiterated RatingBuy$34.00N/A
12/5/2019Maxim GroupReiterated RatingBuy$25.00Low
12/4/2019Needham & Company LLCReiterated RatingHoldHigh
12/2/2019HC WainwrightReiterated RatingBuy$35.00 ➝ $34.00Medium
11/15/2019WedbushReiterated RatingHold$18.00Low
11/13/2019Needham & Company LLCReiterated RatingHoldLow
11/5/2019HC WainwrightReiterated RatingBuy$35.00High
10/30/2019HC WainwrightReiterated RatingBuy$35.00High
10/28/2019WedbushReiterated RatingHold$18.00Low
9/18/2019HC WainwrightSet Price TargetBuy$35.00Low
8/9/2019Maxim GroupSet Price TargetBuy$32.00High
7/15/2019WedbushReiterated RatingNeutral$18.00Medium
5/28/2019HC WainwrightSet Price TargetBuy$35.00Medium
5/20/2019WedbushReiterated RatingHold$18.00Medium
5/6/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$26.00Low
3/4/2019HC WainwrightReiterated RatingBuy$35.00High
12/13/2018HC WainwrightSet Price TargetBuy$34.00High
12/6/2018Maxim GroupSet Price TargetBuy$32.00Medium
12/4/2018HC WainwrightReiterated RatingBuy$34.00High
11/9/2018Maxim GroupReiterated RatingBuy$32.00High
10/24/2018HC WainwrightSet Price TargetBuy$34.00High
10/15/2018HC WainwrightSet Price TargetBuy$34.00Medium
8/29/2018HC WainwrightSet Price TargetBuy$34.00Low
8/28/2018Maxim GroupReiterated RatingBuy$32.00Low
8/10/2018WedbushSet Price TargetHold$20.00High
8/10/2018Maxim GroupBoost Price TargetBuy ➝ Buy$25.00 ➝ $32.00N/A
8/6/2018HC WainwrightSet Price TargetBuy$34.00Low
7/24/2018HC WainwrightSet Price TargetBuy$34.00High
7/18/2018HC WainwrightSet Price TargetBuy$34.00Low
7/12/2018Seaport Global SecuritiesInitiated CoverageBuy$30.00High
6/28/2018HC WainwrightReiterated RatingBuy$34.00Medium
5/25/2018HC WainwrightSet Price TargetBuy$34.00Low
5/16/2018WedbushReiterated RatingNeutral ➝ Hold$19.00 ➝ $20.00Low
5/13/2018Maxim GroupSet Price TargetBuy$25.00High
5/11/2018HC WainwrightSet Price TargetBuy$34.00High
5/7/2018Maxim GroupReiterated RatingBuy$25.00Medium
5/3/2018HC WainwrightSet Price TargetBuy$34.00Medium
4/4/2018HC WainwrightSet Price TargetBuy$34.00High
3/26/2018WBB SecuritiesReiterated RatingBuy$75.00High
3/23/2018HC WainwrightReiterated RatingBuy$34.00High
3/23/2018WedbushDowngradeOutperform ➝ Neutral$47.00 ➝ $19.00High
3/22/2018Maxim GroupBoost Price TargetBuy ➝ Buy$24.00 ➝ $25.00Medium
3/5/2018HC WainwrightSet Price TargetBuy$30.00Medium
3/2/2018Needham & Company LLCDowngradeBuy ➝ Hold$9.01High
3/2/2018Maxim GroupSet Price TargetBuy$24.00High
3/1/2018Cantor FitzgeraldSet Price TargetHold$19.00High
2/19/2018HC WainwrightSet Price TargetBuy$30.00Low
2/15/2018Maxim GroupSet Price TargetBuy$24.00Medium
2/14/2018Bank of AmericaBoost Price Target$2.44 ➝ $4.00Low
1/23/2018HC WainwrightSet Price TargetBuy$30.00Low
1/22/2018Maxim GroupSet Price TargetBuy$24.00Low
1/4/2018HC WainwrightSet Price TargetBuy$30.00Low
1/3/2018Maxim GroupSet Price TargetBuy$24.00Low
12/14/2017HC WainwrightSet Price TargetBuy$30.00Low
12/12/2017Maxim GroupSet Price TargetBuy$24.00High
11/29/2017HC WainwrightSet Price TargetBuy$30.00High
11/28/2017WedbushReiterated RatingOutperform$47.00High
11/8/2017HC WainwrightInitiated CoverageBuy$30.00N/A
11/6/2017Maxim GroupReiterated RatingBuy$24.00N/A
11/2/2017CowenDowngradeOutperform ➝ Market PerformN/A
10/27/2017Maxim GroupReiterated RatingBuy$24.00N/A
10/20/2017Maxim GroupSet Price TargetBuy$24.00N/A
8/24/2017Cantor FitzgeraldReiterated RatingHold$15.00 ➝ $19.00High
8/18/2017WedbushReiterated RatingOutperform$47.00Low
8/8/2017Maxim GroupReiterated RatingBuy$23.00 ➝ $24.00High
8/2/2017Maxim GroupSet Price TargetBuy$23.00 ➝ $24.00Medium
6/14/2017WBB SecuritiesReiterated RatingStrong-Buy$75.00High
6/14/2017WedbushReiterated RatingOutperform$47.00High
6/13/2017Maxim GroupSet Price TargetBuy$23.00High
6/13/2017Cantor FitzgeraldSet Price TargetHold$15.00High
6/3/2017CowenReiterated RatingOutperformMedium
5/22/2017Maxim GroupSet Price TargetBuy$22.00 ➝ $23.00Low
5/11/2017Maxim GroupSet Price TargetBuy$23.00High
5/11/2017Cantor FitzgeraldDowngradeBuy ➝ Neutral$21.00 ➝ $15.00High
5/10/2017WedbushReiterated RatingOutperform$47.00Low
4/3/2017WedbushReiterated RatingOutperform$47.00Low
4/1/2017(FBRC)Reiterated RatingBuyLow
3/30/2017WBB SecuritiesReiterated RatingBuy$75.00Medium
3/27/2017Maxim GroupReiterated RatingBuy ➝ Buy$22.00High
3/20/2017CowenReiterated RatingOutperformHigh
3/17/2017Cantor FitzgeraldReiterated RatingOverweight$21.00High
3/17/2017Maxim GroupReiterated RatingBuy ➝ Buy$19.00 ➝ $22.00High
3/17/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$24.00 ➝ $22.00High
3/11/2017Maxim GroupSet Price TargetBuy$19.00Medium
3/2/2017(FBRC)Reiterated RatingBuyN/A
3/1/2017Maxim GroupReiterated RatingBuyN/A
2/21/2017WedbushReiterated RatingOutperform$47.00N/A
2/8/2017WedbushReiterated RatingOutperform$47.00N/A
1/5/2017WedbushReiterated RatingOutperform$47.00N/A
12/5/2016UBS GroupReiterated RatingReduceN/A
11/17/2016WBB SecuritiesReiterated RatingBuy$75.00N/A
11/16/2016WedbushLower Price TargetOutperform$56.00 ➝ $47.00N/A
11/11/2016Cantor FitzgeraldReiterated RatingBuy$21.00N/A
11/10/2016(FBRC)Reiterated RatingBuyN/A
11/10/2016Needham & Company LLCLower Price TargetBuy$28.00 ➝ $24.00N/A
11/2/2016Maxim GroupSet Price TargetBuy$19.00N/A
10/21/2016WedbushReiterated RatingOutperform$56.00N/A
10/18/2016(FBRC)Reiterated RatingOutperform$38.00N/A
10/18/2016Maxim GroupReiterated RatingBuy$19.00N/A
10/17/2016Cantor FitzgeraldReiterated RatingBuy$21.00N/A
10/17/2016WBB SecuritiesReiterated RatingBuy$75.00N/A
10/17/2016S&P Equity ResearchBoost Price Target$7.65 ➝ $8.63N/A
8/11/2016WedbushReiterated RatingOutperform$62.00 ➝ $56.00N/A
8/10/2016Cantor FitzgeraldReiterated RatingBuy$21.00N/A
8/10/2016Maxim GroupLower Price TargetBuy$30.00 ➝ $19.00N/A
7/28/2016Maxim GroupReiterated RatingBuy$30.00N/A
6/29/2016(FBRC)Reiterated RatingOutperform$38.00N/A
(Data available from 6/21/2016 forward)
Omeros logo
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $15.30
Low: $15.03
High: $15.38

50 Day Range

MA: $16.83
Low: $14.81
High: $19.13

52 Week Range

Now: $15.30
Low: $9.25
High: $25.46

Volume

21,801 shs

Average Volume

692,395 shs

Market Capitalization

$953.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Omeros?

The following sell-side analysts have issued reports on Omeros in the last twelve months: Bank of America Co., HC Wainwright, Maxim Group, UBS Group AG, WBB Securities, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for OMER.

What is the current price target for Omeros?

6 Wall Street analysts have set twelve-month price targets for Omeros in the last year. Their average twelve-month price target is $35.83, suggesting a possible upside of 137.9%. WBB Securities has the highest price target set, predicting OMER will reach $100.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $12.00 for Omeros in the next year.
View the latest price targets for OMER.

What is the current consensus analyst rating for Omeros?

Omeros currently has 1 hold rating, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OMER will outperform the market and that investors should add to their positions of Omeros.
View the latest ratings for OMER.

What other companies compete with Omeros?

How do I contact Omeros' investor relations team?

Omeros' physical mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company's listed phone number is 206-676-5000. The official website for Omeros is www.omeros.com.